CN114222571A - 索格列净治疗患2型糖尿病和中度肾损害的患者的用途 - Google Patents

索格列净治疗患2型糖尿病和中度肾损害的患者的用途 Download PDF

Info

Publication number
CN114222571A
CN114222571A CN202080053637.0A CN202080053637A CN114222571A CN 114222571 A CN114222571 A CN 114222571A CN 202080053637 A CN202080053637 A CN 202080053637A CN 114222571 A CN114222571 A CN 114222571A
Authority
CN
China
Prior art keywords
suggestin
diabetes
dose
type
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202080053637.0A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·布雷格曼
阿里·哈里里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lexicon Pharmaceuticals Inc
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CN114222571A publication Critical patent/CN114222571A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080053637.0A 2019-07-25 2020-07-24 索格列净治疗患2型糖尿病和中度肾损害的患者的用途 Withdrawn CN114222571A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188477.4A EP3769767A1 (en) 2019-07-25 2019-07-25 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
EP19188477.4 2019-07-25
PCT/IB2020/057016 WO2021014420A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Publications (1)

Publication Number Publication Date
CN114222571A true CN114222571A (zh) 2022-03-22

Family

ID=67438963

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053637.0A Withdrawn CN114222571A (zh) 2019-07-25 2020-07-24 索格列净治疗患2型糖尿病和中度肾损害的患者的用途

Country Status (7)

Country Link
US (1) US20220265690A1 (cg-RX-API-DMAC7.html)
EP (2) EP3769767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541322A (cg-RX-API-DMAC7.html)
CN (1) CN114222571A (cg-RX-API-DMAC7.html)
AU (1) AU2020319164A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148400A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014420A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010959A2 (en) 2006-07-14 2008-01-24 The Trustees Of The University Of Pennsylvania Beam ablation lithography

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B ZAMBROWICZ 等: ""LX4211, a Dual SG LT1/SG LT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial"", 《CLINICAL TRIAL》, vol. 92, no. 2, pages 158 - 169, XP055193077, DOI: 10.1038/clpt.2012.58 *
BRIAN ZAMBROWICZ 等: ""LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion"", 《CLINICAL THERAPEUTICS》, vol. 37, no. 1, pages 71 - 82 *

Also Published As

Publication number Publication date
CA3148400A1 (en) 2021-01-28
WO2021014420A1 (en) 2021-01-28
EP4003366A1 (en) 2022-06-01
US20220265690A1 (en) 2022-08-25
JP2022541322A (ja) 2022-09-22
EP3769767A1 (en) 2021-01-27
AU2020319164A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US20240115708A1 (en) Dosing Regimens For The Treatment Of Fabry Disease
Matthaei et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes
Cherney et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Danne et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study
Kaku et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial
Mosley et al. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview
Jabbour et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
Shestakova et al. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
Galvão De Lima et al. Baseline variables associated with early death and extended survival on dialysis
HK40062957A (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
Bellomo Damato et al. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
CN114286682A (zh) 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
AU2020319164A1 (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
JP7482146B2 (ja) 1型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用
Majda et al. Levofloxacin-induced life-threatening hypoglycemia in a type 2 diabetic patient with ST-segment elevation myocardial infarction and community-acquired pneumonia
Helu et al. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study
Saikia et al. Dapagliflozin efficacy as an add-on therapy in double and triple-drug regimens: A meta-analysis of randomized control trial
Hammond et al. Antihypertensive effect of Dapagliflozin in Type II diabetic patients with Hypertension
Gupta 25 Intensive Glycemic Control: Is it
HK40036814A (en) Dosing regimens for the treatment of fabry disease
HK40051480A (en) Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
Saikia DAPAGLIFLOZIN EFFICACY AS AN ADD-ON THERAPY IN DOUBLE AND TRIPLE-DRUG REGIMENS.
CN114694792A (zh) 评价葡萄糖激酶激活剂治疗糖尿病疗效和安全性的方法
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062957

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220322